Boehringer Ingelheim announced that the U.S. FDA granted breakthrough therapy designation for spesolimab as an investigational treatment for the prevention of flares in adults with generalized pustular psoriasis (GPP). GPP is a rare and potentially life-threatening chronic neutrophilic skin disease characterized by flares of widespread eruptions of painful, sterile pustules across the body. Flares greatly affect a person’s quality of life and can lead to hospitalization with serious com...